Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2. (8th July 2022)

• Record Type: Journal Article
• Authors: Chen, Runqiang; Xie, Hui; Khorsandzadeh, Sahba; Smith, Madison; Shaabani, Namir; Hu, Qidong; Lyu, Xiaoxuan; Wang, Hua; Lim, Wan-lin; Sun, Haotian; Ji, Henry; Cooley, Brian; Ross, Russell; Francis, David M
• Editors: Su, Bing
• Is Part Of: Journal of molecular cell biology. Volume 14:Number 6(2022)
• Publication Date: 2022-07-08
• Subjects: COVID-19 -- lymph nodes -- lymphatics -- vaccines -- drug delivery; Molecular biology -- Periodicals; 571.605
• DOI: 10.1093/jmcb/mjac041
• Languages: English
• ISSNs: 1674-2788

Abstract

Abstract: The exploration and identification of safe and effective vaccines for the SARS-CoV-2 pandemic have captured the world's attention and remains an ongoing issue due to concerns of balancing protection against emerging variants of concern while also generating long-lasting immunity. Here, we report the synthesis of a novel messenger ribonucleic acid encoding the spike protein in a lipid nanoparticle formulation (STI-7264) that generates robust humoral and cellular immunity following immunization of C57Bl6 mice. In an effort to improve immunity, a clinically focused lymphatic drug delivery device (MuVaxx) was engineered to modulate immune cells at the injection site (epidermis and dermis) and draining lymph node (LN) and tested to measure adaptive immunity. Using MuVaxx, immune responses were elicited and maintained at a 10-fold dose reduction compared to traditional intramuscular (IM) administration as measured by anti-spike antibodies, cytokine-producing CD8 T cells, neutralizing antibodies against the Washington (wild type) strain and South African (Beta) variants, and LN-resident spike-specific memory B cells. Remarkably, a 4-fold-elevated T cell response was observed in MuVaxx-administered vaccination compared to that of IM-administered vaccination. Thus, these data support further investigation into STI-7264 and lymphatic-mediated delivery using MuVaxx for SARS-CoV-2 and VoC vaccines.